7TM raises $15 million and sells assets to OSI
This article was originally published in Scrip
Executive Summary
7TM Pharma, a privately held Danish biotech company, has raised DKK75 million ($15 million) to develop its treatments for metabolic disorders and obesity. The company's lead product, obinepitide, a synthetic analogue of PYY3-36 and a pancreatic polypeptide, is currently in Phase I/II trials for the treatment of obesity. 7TM's other products include TM30339, a Y4-selective agonist, which has completed clinical Phase I studies and has begun Phase I/II studies in obesity. The company has also developed TM38837 in preclinical studies in obesity and diabetes. The product has been designed to reduce central nervous system-related side-effects associated with other centrally acting CB1 antagonists (most of these products have been dropped from development following the failure of Sanofi-Aventis's Acomplia (rimonabant)). In addition to the financing, 7TM has also sold certain early-stage discovery and technology assets toOSI Pharmaceuticals. The company will help establish the technology at OSI's subsidiary OSI (Prosidion). 7TM expects to have sufficient cash to the end of 2010.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.